Diabetes subphenotypes and metabolomics: The key to discovering laboratory markers for personalized medicine?

Clinical Chemistry

Volumn 59, Issue 9, 2013, Pages 1294-1296

  Lehmann, Rainer ^a,b,c  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLCARNITINE; BIOLOGICAL MARKER; BRANCHED CHAIN AMINO ACID; C PEPTIDE; FATTY ACID; HEMOGLOBIN A1C; INSULIN; LINOLEIC ACID; LYSOPHOSPHATIDYLCHOLINE; OLEIC ACID; PRASTERONE SULFATE;

BIOINFORMATICS; BLOOD LEVEL; EARLY DIAGNOSIS; GENETIC SCREENING; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; ISOLATED POSTCHALLENGE DIABETES; LABORATORY DIAGNOSIS; LABORATORY TEST; METABOLOMICS; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PATIENT IDENTIFICATION; PERSONALIZED MEDICINE; PHENOTYPE; REVIEW; VALIDITY;

DEHYDROEPIANDROSTERONE SULFATE; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; HUMANS; LIPIDS; MALE; METABOLOMICS;

EID: 84883382509     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2013.207993     Document Type: Review

References (15)

1. WHO. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of WHO/IDF consultation. Geneva: WHO; 2006. http://whqlibdoc.who.int/publications/2006/9241594934-eng.pdf (Accessed June 2013).
2. Morris AP, Voight BF, Teslovich TM, Ferreira T, Segre AV, Steinthorsdottir V, et al. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet 2012;44:981-90.
3. Stefan N, Kantartzis K, Machann J, Schick F, Thamer C, Rittig K, et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med 2008;168:1609-16.
4. Stefan N, Haring HU. The metabolically benign and malignant fatty liver. Diabetes 2011;60:2011-7.
5. Rhee EP, Gerszten RE. Metabolomics and cardiovascular biomarker discovery. Clin Chem 2012;58:139-47.
6. Liu L, Wang M, Yang X, Bi M, Na L, Niu Y, et al. Fasting serum lipid and dehydroepiandrosterone sulfate as important metabolites for detecting isolated postchallenge diabetes: serum metabolomics via ultra-highperformance LC-MS. Clin Chem 2013;59:1338-48.
7. Lehmann R, Franken H, Dammeier S, Rosenbaum L, Kantartzis K, Peter A, et al. Circulating lysophosphatidylcholines are markers of a metabolically benign nonalcoholic fatty liver. Diabetes Care 2013;36:2331-8.
8. Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, et al. Metabolite profiles and the risk of developing diabetes. Nat Med 2011;17: 448-53.
9. Newgard CB. Interplay between lipids and branched-chain amino acids in development of insulin resistance. Cell Metab 2012;15:606-14.
10. Floegel A, Stefan N, Yu Z, Muhlenbruch K, Drogan D, Joost, HG, et al. Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach. Diabetes 2012;62:639-48.
11. Wang-Sattler R, Yu Z, Herder C, Messias AC, Floegel A, He Y, et al. Novel biomarkers for pre-diabetes identified by metabolomics. Mol Syst Biol 2012; 8:615.
12. Ho JE, Larson MG, Vasan RS, Ghorbani A, Cheng S, Rhee EP, et al. Metabolite profiles during oral glucose challenge. Diabetes 2013;62:2689-98.
13. Yin P, Peter A, Franken H, Zhao X, Neukamm SS, Rosenbaum L, et al. Preanalytical aspects and sample quality assessment in metabolomics studies of human blood. Clin Chem 2013;59:833-45.
14. Wolf M, Chen S, Zhao X, Scheler M, Irmler M, Staiger H, et al. Production and release of acylcarnitines by primary myotubes reflect the differences in fasting fat oxidation of the donors. J Clin Endocrinol Metab 2013;98: E1137- 42.
15. Dutta T, Chai HS, Ward LE, Ghosh A, Persson XM, Ford GC, et al. Concordance of changes in metabolic pathways based on plasma metabolomics and skeletal muscle transcriptomics in type 1 diabetes. Diabetes 2012;61:1004-16.